CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for InterMune Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

InterMune Inc.
3280 Bayshore Blvd
Phone: (415) 466-2200p:415 466-2200 BRISBANE, CA  94005  United States Ticker: ITMNITMN

This company was Merged or Acquired on 9/26/2014.
This company ceased filing statements with the SEC on 10/27/2014.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
InterMune, Inc. (InterMune) is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. Pulmonology is the field of medicine concerned with the diagnosis and treatment of lung conditions. The Company has a product in pulmonology, pirfenidone, which is an orally active, small molecule compound. On January 2, 2013, it began the commercial launch of Esbriet in Canada. IPF is a disease characterized by progressive scarring, or fibrosis, of the lungs, which leads to their deterioration and destruction. The prognosis is poor for patients with IPF, which occurs primarily in persons 40 to 70 years old with a median survival time from diagnosis of two to five years. Pirfenidone in Japan is sold by Shionogi under the brand name Pirespa. Pirfenidone in India is sold by Cipla Ltd. under the brand name Pirfenex, and in China is sold by Shanghai Genomics. In September 2014, Roche Holding AG acquired InterMune.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201412/31/2013YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, President, Chief Executive Officer Daniel G.Welch 56 5/13/2008 9/25/2003
Executive Vice President - Finance, Chief Financial Officer John C.Hodgman 59 3/1/2013 8/14/2006
Executive Vice President, General Counsel, Corporate Secretary Andrew K.Powell 56 9/24/2013 9/24/2013
9 additional Officers and Directors records available in full report.

Business Names
Business Name
InterMune Austria GmbH
InterMune Benelux B.V.
InterMune Bristol Ltd.
13 additional Business Names available in full report.

General Information
Number of Employees: 353 (As of 12/31/2013)
Outstanding Shares: 107,969,163 (As of 7/31/2014)
Shareholders: 61
Stock Exchange: NASD
Federal Tax Id: 943296648
Fax Number: (415) 466-2300
Email Address: ir@intermune.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023